Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 3,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Protein Control Clear all

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin glargine, 300 U/ml, Insulin degludec, 100U/ml, Background therapy: Rapid acting insulin analogs; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Crohn Disease, Rectal Fistula
Interventions: EUA with seton placement if necessary, adalimumab, EUS; Procedure · Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
Interventions: 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin, Atezolizumab, Cobimetinib, Ramucirumab, Paclitaxel, PEGylated recombinant human hyaluronidase (PEGPH20), BL-8040, Linagliptin, Cisplatin, Tiragolumab; Drug · Biological
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 6
States / cities: Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 3 more

Conditions: Type 2 Diabetes, Overweight, Obesity
Interventions: Tirzepatide, Placebo; Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 938 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 43
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Huntington Park, California + 39 more

Conditions: Persian Gulf Syndrome
Interventions: Carnosine, Placebo; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 34 Years to 82 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Urticaria
Interventions: Omalizumab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 40
States / cities: Granada Hills, California • Long Beach, California • Los Angeles, California + 36 more

Conditions: Anesthesia, Opioid Use
Interventions: Guided mindfulness exercises, Self-administered aromatherapy, Baby aspirin, Tylenol/Acetaminophen, Pregabalin, Prednisone, Meloxicam, Prilosec, Tramadol, Voltaren, Zofran, Pepcid, Reglan, Versed, Lidocaine, Propofol, Ancef, Tranexamic Acid (TXA), Decadron, Bupivacaine hydrochloride, Toradol; Behavioral · Other · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: Ketogenic diet, Low-fat Mixed diet; Dietary Supplement
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Food Insecurity
Interventions: Food support; Other
Lead sponsor: Alaska Native Tribal Health Consortium; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Bethel, Alaska

Conditions: Neuroma
Interventions: onabotulinum toxin type-A, placebo, 2nd phase - onabotulinum toxin type-A; Drug · Other
Lead sponsor: Southern Illinois University; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Springfield, Illinois

Conditions: Heart Failure, Congestive and Microalbuminuria
Interventions: metoprolol xl, carvedilol MR, lisinopril; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 72
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 60 more

Conditions: Prehypertension
Interventions: Marealis refined peptide concentrate, Placebo; Dietary Supplement
Lead sponsor: KGK Science Inc.; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Healthy Subjects
Interventions: Exenatide, Moxifloxacin, Placebo comparator; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 2
States / cities: Daytona Beach, Florida • Evansville, Indiana

Conditions: Hematopoietic and Lymphatic System Neoplasm
Interventions: SARS-CoV-2 mRNA Vaccine ARCT-021, Tozinameran, Biospecimen Collection, Electronic Health Record Review, Survey Administration; Biological · Procedure · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Schizophrenia
Interventions: D-cycloserine, Placebo, Cognitive Remediation; Drug · Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus
Interventions: Aliskiren + Valsartan; Drug
Lead sponsor: HeartDrug Research LLC; Other
Eligibility: 21 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Digestion
Interventions: Beef protein, Chocolate whey protein; Dietary Supplement
Lead sponsor: Efforia, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Pain, Postoperative
Interventions: Gabapentin, Acetaminophen, Celecoxib; Drug
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years and older · Female only
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Dysphagia
Interventions: Proactive pharyngeal-laryngeal Exercise Program, Premier Protein Clear ® High Protein, Hydration Counseling; Behavioral · Dietary Supplement
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years to 99 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma
Interventions: Collection of trabecular meshwork tissue during surgery; Other
Lead sponsor: Wills Eye; Other
Eligibility: 21 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Idiopathic Urticaria
Interventions: etanercept, placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Peanut Allergy
Interventions: Tezepelumab, Peanut Oral Immunotherapy (OIT), Placebo for Tezepelumab; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 55 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 10
States / cities: Little Rock, Arkansas • Los Angeles, California • Baltimore, Maryland + 6 more

Conditions: Hypertension in Pregnancy
Interventions: Enalapril 10mg QD, Nifedipine 30mg XL BID; Drug
Lead sponsor: Nebraska Methodist Health System; Other
Eligibility: 19 Years and older · Female only
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Type 1 Diabetes Mellitus
Interventions: Frexalimab, Placebo, Insulin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 14
States / cities: San Francisco, California • Aurora, Colorado • Gainesville, Florida + 11 more

Search by objective public record fields.

Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients

Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn's Perianal Fistulas

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight

Treatment Study of Carnosine Versus Placebo in Gulf War Illness (GWI)

A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria

PROUD Study - Preventing Opioid Use Disorders

Ketogenic Diet vs Mixed Diet in Patients With Heart Failure

YK Delta Food Box Study

Botulinum Toxin Type A for Neuroma Pain

COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria

Effect and Safety of Marealis RPC (Refined Peptide Concentrate) in Mild or Moderate Hypertensive Subjects

A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects

Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients

D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia

Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics

Beef Versus Whey Protein: The Gut Showdown Self-Experiment

Single Dose Preoperative Gabapentin Use in Minimally Invasive Hysterectomy for Acute Pain Management

Anterior Cervical Discectomy and Fusion (ACDF) - Behavioral Intervention

The Changes Within the Cells of the Drainage System of the Eye in Patients With Glaucoma

Etanercept for the Treatment of Chronic Urticaria

Efficacy of Tezepelumab in Peanut Oral Immunotherapy

Postpartum Evaluation of Nifedipine and Enalapril for Hypertension

Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)